Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23371352 | 0.79 | CYP2D6 (0.43) | HDAC4 | |
| SCHEMBL7930611 | 0.79 | PTGS2 (0.44) | ERN1RAB9ANPC1KMT2ALMNA | |
| SCHEMBL13584852 | 0.79 | ABCG2 (0.46) | ERN1KMT2ASMN1; SMN2NFE2L2 | |
| SCHEMBL5852340 | 0.79 | MEN1 (0.55) | ERN1RAB9ANPC1KMT2AMAPK14 | |
| SCHEMBL14840347 | 0.79 | ERN1 (0.49) | ERN1RAB9ANPC1LMNAMAPK14 | |
| SCHEMBL2687037 | 0.76 | SLC40A1 (0.39) | ERN1RAB9ANPC1LMNAHPGD | |
| SCHEMBL29912312 | 0.76 | SLC40A1 (0.39) | ERN1RAB9ANPC1LMNAHPGD | |
| SCHEMBL13388033 | 0.76 | ERN1 (0.44) | ERN1NFE2L2ADORA2AADORA1 | |
| SCHEMBL3637569 | 0.75 | NPC1 (0.46) | RAB9ANPC1PKMKMT2ALMNA | |
| SCHEMBL19127415 | 0.75 | ABL1 (0.45) | RAB9ANPC1PKMSMN1; SMN2NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174272-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| US-20210206781-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2021-07-08 | — | — | US | disclosed |
| US-9440990-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150376205-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-31 | — | — | US | disclosed |
| US-8648079-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20130090341-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376205-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, PSEN1, HTT | ERN1 2218/4885RAB9A 1595/4885NPC1 55/4885 |
| US-11174272-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | ERN1 2281/4885RAB9A 1428/4885NPC1 90/4885 |
| US-20130090341-A1 | HETEROCYCLIC COMPOUNDS | HTT, NQO1, BDNF | ERN1 3895/4885RAB9A 1801/4885NPC1 152/4885 |
| US-20210206781-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | ERN1 2281/4885RAB9A 1428/4885NPC1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.